LIPITOR
Ranbaxy can only sell US-made Lipitor copy
The US Food and Drug Administration has allowed Ranbaxy to manufacture generic Lipitor at Ohm Labs facility in the US for American market.
Dr Reddy's launches Atorvastatin calcium tablets in US
Dr Reddy's said that it has launched Atorvastatin calcium tablets, a bioequivalent generic version of Lipitor tablets in the US.
Five retailers led by Walgreen sue Pfizer, Ranbaxy for Lipitor generic delay
Five big retailers led by Walgreen have sued Pfizer and Ranbaxy for allegedly delaying launch of the Indian company's low-cost version of Lipitor in the US.
Lipitor prescription dips 50%, boost for Ranbaxy
Share price of Ranbaxy Laboratories gained 3% after reports said that prescription of Pfizer’s cholesterol lowering drug Lipitor fell by 50% within two weeks of the launch of a generic version by the Indian drug maker.
Ranbaxy set to get USFDA nod for Lipitor generic launch
"The FDA has been very positive about Ranbaxy's intent to launch the product and we are working towards meeting the launch timeline", a person said.
Watson starts selling generic Lipitor in US, Ranbaxy mum
US-based Watson Pharmaceuticals said it has launched in US market the generic version of cholesterol lowering drug Lipitor following the expiry of Pfizer's patent.
Ranbaxy struggling to get approvals for Lipitor; stock down
Shares of Ranbaxy were trading lower in early trade on Wednesday, following reports that the company is still struggling to get approvals for Lipitor.
Lipitor goes off patent today, Pfizer vs Ranbaxy-led Indian pharma's war for blockbuster drugs intensifies
But for Indian companies, it was not always supposed to be like this. The end of Lipitor’s patent was meant to be a eureka moment for Ranbaxy.
Pfizer fights to retain Lipitor market share
The move is expected to hit Ranbaxy Pharma, which has the exclusive rights to sell the generic version for three months beginning November 30.
Pfizer marketing may hit Ranbaxy’s profit from low-cost lipitor version
Late last year, Pfizer started offering ‘co-pay’ programmes which lowered out of pocket payment by insured patients to $4 a month for a Lipitor prescription.
Ranbaxy: Uncertainty over Lipitor keeps investors edgy
With resolution of FDA issues pending, it is also not clear whether Ranbaxy will be allowed to launch the Lipitor generic.
Ranbaxy and Pfizer sued for delay in launch of Lipitor in US
A group of US pharmacies filed lawsuit against Ranbaxy, Pfizer & accused the two drug firms of delaying the launch of Lipitor in the US
Ranbaxy Laboratories to roll out Lipitor Clone in US on Nov 30
Following a settlement in 2008, Pfizer Inc gave Ranbaxy exclusive marketing rights to sell Lipitor's low-cost version for six months.
Pfizer, Dr Reddy's settle patent suit over Lipitor
Pfizer's Lipitor is the world's largest-selling drug, which generated about $7 billion in sales last year in the US alone.
Pfizer resuming ads for Lipitor after controversy
Television ads for the world's top-selling drug, cholesterol fighter Lipitor, are back, six months after Pfizer Inc pulled them amid charges its use of a celebrity doctor endorser who's never practiced medicine misled the public.
Ranbaxy can advance Lipitor in Australia
In A mixed verdict for Ranbaxy Laboratories in its ongoing battle to launch a generic version of anti-cholesterol drug Lipitor, a full federal court of Australia has upheld an earlier decision which had gone in its favour. However, the court said that Ranbaxy’s generic drug infringes upon another patent of Pfizer’s patent for the same drug.
Partial win for Ranbaxy in Lipitor case
In a partial victory for Ranbaxy Laboratories in its patent litigation against Pfizer, an Australian court has ruled in the Indian company's favour in a case relating to cholesterol lowering drug atorvastatin (Lipitor).
Pfizer again sues Ranbaxy over Lipitor
Pfizer has filed two separate patent infringement cases against Ranbaxy in a bid to extend the exclusivity of its $13-billion anti-cholesterol drug Lipitor. Health insurance
Netherlands court stops Ranbaxy from launching Lipitor
An appellate court in the Netherlands has restrained India's largest drug firm Ranbaxy Laboratories Ltd from launching a generic version of cholesterol-lowering drug Lipitor in the country before November 2011.
Load More
